Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EBT (2024 - 2025)

Kura Oncology (KURA) has disclosed EBT for 2 consecutive years, with -$80.9 million as the latest value for Q4 2025.

  • Quarterly EBT fell 370.54% to -$80.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$278.4 million through Dec 2025, down 61.88% year-over-year, with the annual reading at -$278.4 million for FY2025, 61.88% down from the prior year.
  • EBT for Q4 2025 was -$80.9 million at Kura Oncology, down from -$74.1 million in the prior quarter.
  • The five-year high for EBT was -$17.2 million in Q4 2024, with the low at -$80.9 million in Q4 2025.